Group 1 - The core point of the news is that Hefei Lifan Pharmaceutical Co., Ltd. has completed the share reduction plan by shareholder Gao Meihua, who reduced her holdings by 300,000 shares, accounting for 0.16% of the company's total share capital [1][2][3] Group 2 - The specific details of the reduction indicate that Gao Meihua executed the reduction through centralized bidding from July 28, 2025, to August 29, 2025, at an average price of 29.71 yuan per share, with a total of 300,000 shares reduced [2] - Prior to the reduction, Gao Meihua held 6,444,703 shares, representing 3.37% of the total share capital, which decreased to 6,144,703 shares, or 3.23%, after the reduction [2] - The shares reduced were sourced from shares held before the company's initial public offering and from capital reserve converted into share capital [2] Group 3 - The reduction complies with the relevant laws and regulations, including the Securities Law of the People's Republic of China and the Shenzhen Stock Exchange Listing Rules [3] - The implementation of this reduction plan does not lead to a change in the company's control or significantly impact its governance structure and future operations [3] - The company has indicated that the market should pay attention to its future development dynamics following the completion of this reduction plan [4]

格隆汇9月2日丨立方制药(003020.SZ)公布，近日，公司收到股东高美华女士出具的《关于股份减持计 划实施完毕的告知函》，获悉高美华女士本次减持计划已经实施完毕，累计减持30万股，减持比例 0.16%。 ...

证券代码：003020 证券简称：立方制药 公告编号：2025-068 合肥立方制药股份有限公司 关于股东减持计划实施完毕的公告 公司股东高美华女士保证向本公司提供的信息内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、股东减持情况 1、股东减持股份情况 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 合肥立方制药股份有限公司（以下简称"立方制药"或"公司"）于 2025 年 6 月 6 日披露了《关于部分董事、监事、高级管理人员及股东减持股份的预披 露公告》（公告编号：2025-043），公司股东高美华女士计划于减持计划披露之 日起 3 个交易日后的 3 个月内以集中竞价方式或大宗交易方式减持公司股份不超 过 300,000 股（占公司总股本比例 0.16%）。近日，公司收到高美华女士出具的 《关于股份减持计划实施完毕的告知函》，获悉高美华女士本次减持计划已经实 施完毕。现将具体情况公告如下： | 股东名称 | 减持方式 | | 减持期间 | | | 减持均价 （元/股） | 减持股数 （万股） | 减持比例 | | --- | --- | --- | --- ...

Market Performance - The A-share market collectively rose on September 1, with the Shanghai Composite Index increasing by 0.46%, the Shenzhen Component Index rising by 1.05%, and the ChiNext Index surging by 2.29%, while the Beijing Stock Exchange 50 fell by 0.36% [2] - The total trading volume in the Shanghai and Shenzhen markets was 27,776 billion yuan, a decrease of 525 billion yuan compared to the previous day [2] - Over 3,200 stocks in the market experienced gains [2] Sector Performance - The leading sectors in terms of gains included precious metals, non-ferrous metals, innovative pharmaceuticals, CPO, and storage chips [2] - Conversely, the sectors that saw declines included insurance, airport and shipping, securities, military equipment, banking, and gaming [2] Notable Stocks - International gold prices surpassed 3,480 USD per ounce, leading to a collective surge in gold stocks, with companies like Zhongjin Gold, Hunan Gold, and Western Gold hitting the daily limit [2] - Innovative pharmaceutical stocks saw significant increases, with Maiwei Biotech hitting the daily limit and over 10 stocks including Lifang Pharmaceutical and Baihua Medicine also reaching the daily limit [2] - CPO concept stocks maintained strong performance, with companies like Zhongji Xuchuang, Tianfu Communication, and Xinyi Sheng reaching historical highs [2] - The satellite navigation and military equipment sectors saw multiple stocks decline, with China Satellite, China Satcom, and Aerospace Hongtu among those with notable losses [2] - The securities sector also underperformed, with Huaxi Securities, Dongwu Securities, and Dongfang Securities experiencing declines [2]

Group 1 - The ophthalmology medical concept stocks experienced a surge during trading, with Sharplife reaching a limit up [1] - Xingqi Eye Medicine rose over 10% in the afternoon session [1] - Lifang Pharmaceutical previously hit the limit up, indicating strong market interest [1] Group 2 - Other companies such as Baicheng Pharmaceutical, Aibo Medical, Guangzheng Eye Care, and He Shi Eye Care also saw increases in their stock prices [1]

Investment Rating - The report provides a positive outlook on the MASH non-invasive diagnosis technology, suggesting it could accelerate new drug development in the pharmaceutical and biotechnology sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.65% from August 25 to August 29, underperforming compared to the Wind All A index (1.9%) and the CSI 300 index (2.71%). Only the medical research outsourcing (4.9%) and other biological products (0.14%) sectors saw gains, while in vitro diagnostics (-4.12%), raw materials (-3.34%), and vaccines (-0.59%) faced significant declines [2][7]. - The FDA has accepted the proposal for using VCTE-LSM as a reasonable alternative endpoint for clinical trials in adults with MASH and moderate to advanced fibrosis. This non-invasive method is expected to enhance patient compliance and could lead to a surge in drug development in the MASH area within the next two to three years [2][13]. - The report emphasizes the potential for domestic companies in China to leverage their cost advantages and forward-looking strategies in the field of non-invasive companion diagnostics, particularly in the MASH drug development competition [2]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance was notably weaker than the broader market indices, with specific sub-sectors like medical research outsourcing and other biological products showing resilience [7][8]. - Individual stocks such as Tianchen Medical (30.1%), Ailis (25.6%), and Maiwei Biotech-U (22.4%) performed well, while stocks like Lifang Pharmaceutical (-13.9%), Yuekang Pharmaceutical (-11.9%), and Kanghua Biotech (-11.1%) faced significant losses [10][12]. Industry News and Key Company Announcements - On August 28, Kangfang Biotech announced that its drug AK112 received approval for treating advanced non-squamous non-small cell lung cancer, with promising clinical trial results expected to be presented at an international conference [12]. - The report highlights various companies' financial performances, with notable revenue changes and profit margins, indicating a mixed outlook across the sector [16][17].

证券代码：003020 证券简称：立方制药 公告编号：2025-067 合肥立方制药股份有限公司 关于完成董事会换届选举及聘任高级管理人员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 合肥立方制药股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日召开 2025 年第一次临时股东大会，选举产生了公司第六届董事会 4 名非独立董事、3 名独立董事，与公司于 2025 年 8 月 29 日召开的职工代表大会选举产生的 1 名职 工代表董事，共同组成了公司第六届董事会。同日，公司召开第六届董事会第一 次会议，选举产生了董事长、副董事长、董事会专门委员会委员，并聘任新一届 高级管理人员。现将具体情况公告如下： 一、第六届董事会组成情况 （一）董事会组成 战略委员会：季俊虬先生（主任委员）、杨模荣先生、李进华先生； 审计委员会：杨模荣先生（主任委员）、史静先生、方芸女士； 1 提名委员会：李进华先生（主任委员）、史静先生、崔欢喜先生； 公司第六届董事会由 8 名董事组成，其中非独立董事 5 名（含职工代表董事 1 名），独立董事 3 名，具体如下 ...

1、本次股东大会未出现否决提案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 证券代码：003020 证券简称：立方制药 公告编号：2025-065 合肥立方制药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、召开时间 （1）现场会议时间：2025 年 8 月 29 日（星期五）下午 14:30。 （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为：2025 年 8 月 29 日 9:15—9:25、9:30—11:30、13:00—15:00；通过深圳证券交易所互联 网投票系统投票的时间为：2025 年 8 月 29 日 9:15-15:00。 2、现场会议召开地点：安徽省合肥市文曲路 446 号科研综合楼五楼会议中 心。 3、会议召开方式：现场投票与网络投票相结合的方式。 4、会议召集人：公司董事会。 5、会议主持人：公司董事长季俊虬先生。 6、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规、规范性文件和《公司章程》 ...

合肥立方制药股份有限公司 证券代码：003020 证券简称：立方制药 公告编号：2025-066 第六届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 同意选举季俊虬先生为公司第六届董事会董事长，任期三年，自本次董事会 决议通过之日起生效。 表决情况：同意 8 票，反对 0 票，弃权 0 票。 1 合肥立方制药股份有限公司（以下简称"公司"）第六届董事会第一次会议 于公司 2025 年第一次临时股东大会、公司职工代表大会选举产生第六届董事会 成员后召开，经全体董事同意豁免本次会议通知期限要求，以口头方式向全体董 事发出会议通知。会议于 2025 年 8 月 29 日下午 16:00 在科研综合楼五楼会议中 心以现场表决的方式召开，会议应出席董事 8 人，实际出席董事 8 人。公司高级 管理人员候选人列席了会议。会议由全体董事共同推举季俊虬先生主持。 本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》《董事会议事规则》的规定。 二、董事会会议审议情况 与会董事经过认真审议并投票表决，审议通过了如下议案： 1 ...

Group 1 - The company held its first extraordinary general meeting of shareholders on August 29, 2025, at 14:30 in Hefei, Anhui Province [1][2] - The meeting was convened following the resolution of the company's fifth board of directors on August 12, 2025, and the notice was published on August 13, 2025 [2][3] - A total of 6 proposals were reviewed during the meeting, including amendments to the company's articles of association and the election of the sixth board of directors [3][4] Group 2 - 17 shareholder representatives attended the meeting in person, representing 18 shareholders, while 123 shareholders participated via online voting, accounting for 4.9058% of the total voting shares [3][4] - The meeting's convenor was the company's board of directors, which met the qualifications set by Chinese laws and the company's articles of association [5] Group 3 - The voting process included both on-site and online voting, with results announced at the meeting [6][7] - The first proposal regarding the amendment of the articles of association was passed with 99.9904% approval from the attending shareholders [6][10] - The election of non-independent directors and independent directors also received significant support, with approval rates around 98.1595% [7][9] Group 4 - The proposal for the three-year dividend return plan (2026-2028) was approved with 99.9638% of the votes [12][13] - The adjustment of independent director allowances was also passed with a similar majority [13]